Skip to main content

Table 2 Characteristics of 22 relapsed lung ADC patients with potential squamous transition

From: Pathological transition as the arising mechanism for drug resistance in lung cancer

Patient ID Gender Age Smoking status Therapy 1st biopsya 2nd biopsyb References
Pathological status Mutation status Pathological status Mutation status
1 F 79 N Chemotherapy ADC EGFR 19 del SCC EGFR 19 del [112]
2 M 43 Y Chemotherapy ADC EGFR 19 del SCC EGFR 19 del [113]
3 F 48 N Gef ADC EGFR 19 del SCC EGFR 19 del [114]
4 F 51 NA Gef ADC EGFR 19 del SCC EGFR 19 del [115]
5 F 58 Y Erl ADC EGFR 19 del SCC EGFR 19 del [116]
6 F 66 N Erl ADC EGFR 19 del SCC EGFR 19 del [117]
7 F 67 NA Afa ADC EGFR 19 del SCC EGFR 19 del and PIK3CA mutation [118]
8 F 40 Y Afa ADC EGFR 19 del SCC EGFR 19 del + T790M [119]
9 F 79 N Gef ADC EGFR 19 del SCC EGFR L858R + T790M [120]
10 M 41 Y Gef ADC EGFR 19 del SCC + SCLC NA [61]
11 F 52 Y Erl + Beva ADC EGFR 19 del SCC EGFR 19 del [121]
12 F 61 N Gef ADC EGFR L858R SCC EGFR L858R [115]
13 M 62 N Gef ADC EGFR L858R SCC EGFR L858R [122]
14 F 63 N Erl ADC EGFR L858R SCC EGFR L858R and PIK3CA [123]
15 F 74 Y Gef ADC EGFR L858R SCC EGFR L858R + T790M [120]
16 M 68 Y Erl ADC EGFR L858R SCC EGFR L858R + T790M [124]
17 F 43 Y Gef ADC EGFR L858R SCC EGFR L858R +S768I [125]
18 F 64 N Gef ADC EGFR L858R + T790M SCC EGFR L858R + T790M [114]
19 F 60 Y ALK TKI ADC ALK SCC ALK [126]
20 F 52 N Crizo/Alec ADC ALK SCC ALK [127]
21 F 63 N Erl ADC WT SCC EGFR L858R + T790M [128]
22 M 69 N Chemotherapy–immunotherapy ADC WT SCC NA [129]
  1. Y yes, N no, NA not available, M male, F female, ADC adenocarcinoma, SCC squamous cell carcinoma, SCLC small cell lung cancer, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor, Gef gefitinib, Erl erlotinib, Afa afatinib, Crizo crizotinib, Alec alectinib, Ceri ceritinib, Beva bevacizumab, ALK anaplastic lymphoma kinase, WT wild type, EGFR 19 del EGFR exon 19 deletion
  2. a1st biopsy: the first biopsy
  3. b2nd biopsy: the second biopsy
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us